Are you looking for a stock?

Try one of these

Related Videos

Valeant CEO talks about Afexa bid

Valeant Pharmaceuticals is looking to add another company to its lengthy list of acquisitions after it announced on Tuesday a friendly $76-million bid for Afexa Life Sciences. Chairman and CEO Mike Pearson talks to BNN about Valeant's offer.
DISLIKE
 
COMMENTS
 
CTV.ca CTV Two CTV News CTV News Channel BNN - Business News Network CP24